Direct oral anticoagulants (DOACs) are used in the treatment of both venous thromboembolism (VTE) and Non-valvular atrial fibrillation (NVAF). The CDC states that VTE affects about 900,000 Americans every year, results in about 100,000 deaths per year, and costs the nation up to 10 billion dollars per year. NVAF is the primary diagonosis of over 450,000 hospitalizations and contributes to about 158,000 deaths each year.

Within Kaiser Permanente, there have been updates in 2022 for the use of DOACs for the treatment of VTE and NVAF. Updates were made to the Kaiser Permamante California Regions Treatment Algorithm for VTE and Interregional practice Recommendations for the treatment of NVAF. These updates reflect the best practices to promote safe prescribing and patient safety as well as refelct the preferred products based on formulary status within Kaiser Permanente.  

The desired outcome of this presentation is to inform prescribers about the updates surrounding direct oral anticoagulants, specifically the Caliofrnia Regions Treatment Algorithm for VTE and Interregional Practice Recommendations for the treatment of Nonvalvular atrial fibrillation. The presentation will facilitate the continuous improvement of quality of care and safety in our patients, especially in patients with venous thromboembolism and non-valvular atrial fibrillation.